BOSS-002, NCT05785390: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. |
|
|
| Recruiting | 2 | 308 | US | NP-101, TQ Formula, Placebo | Novatek Pharmaceuticals | COVID-19 | 10/24 | 10/24 | | |
NCT06217094: Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment |
|
|
| Not yet recruiting | 1 | 18 | NA | NP-101 (3 g), NP-101 (4.8 g), NP-101 (6 g) | University of Florida, Novatek | Hepatocellular Carcinoma | 07/26 | 09/29 | | |